Belgium Drug Report 2017
Belgium
Country Drug Report 2017
About this report
At a glance
NBData presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures). Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.
Sections
What are the long-term aims of drug policy in Belgium? How are these aims to be achieved? How is drug policy coordinated at national level?
Learn moreUnderstanding the costs of drug-related actions is an important aspect of policy evaluation.
Learn moreWhat substances and activities does Belgium control under its drug laws? What are the penalties for offences? How are new psychoactive substances controlled?
Learn moreHow many people in Belgium have ever used drugs? What drugs have they used? How many have used drugs recently? How many are using drugs in highly risky ways?
Learn moreWhat are the main infectious diseases linked to drug injecting in Belgium? How many died of drug overdose in the last year? How many drug-related medical emergencies occurred?
Learn moreWhat part does prevention play in Belgium drug strategy. What are the main prevention approaches used in the country and who do they target?
Learn moreHow does Belgium measure in terms of provision of needle and syringe programmes, peer naloxone programmes, supervised drug consumption rooms and heroin-assisted treatment.
Learn moreHow is the drug treatment system organised in Belgium? How is it financed? How is the provision of treatment divided between inpatient and outpatient settings?
Learn moreWhich authorities are responsible for prison health in Belgium? What forms of drug treatment and harm reduction are provided in prisons, and how widely?
Learn moreWhat is done in Belgium to ensure that the prevention and treatment interventions used are effective and provide a good return on public expenditure?
Learn moreIn which areas of study is drug-related research carried out in Belgium? How is this research funded? Are any types of research emphasised in the national drug strategy?
Learn moreWhat is known about drug supply and trafficking in the Belgium? How pure or strong are the drugs available? What do they cost? What are the main aims of supply reduction efforts?
Learn morePartners
About our partner in Belgium
The national focal point is located within the Epidemiology Unit of the Scientific Institute of Public Health (WIV-ISP). The WIV-ISP is a state (federal) scientific organisation and implements policies in response to the legal framework and priorities of the Federal Minister for Health and the President of the Federal Public Service for Health, Food Chain Security and the Environment. The WIV-ISP is the scientific reference in the field of public health. WIV-ISP supports health policy and policy-making through innovative research, analyses, monitoring activities and expert advice. In this way, WIV-ISP contributes to a healthy life for all. The main tasks of the drugs programme of the WIV-ISP include the monitoring, collection, analysis and dissemination of drug-related information. In order to dispose of national drug-related data, cooperation and coordination with 4 regional partner organisations is vital due to the assigned responsibilities regarding health policy.
Scientific Institute of Public Health
(Institut scientifique de santé publique/Wetenschappelijk Instituut Volkgezondheid)
Rue Juliette Wytsman 14
B-1050 Bruxelles/Brussels
Belgium
Tel. +32 26425034
Fax +32 26425001
Head of national focal point: Ms Lies Gremeaux